View Older Stories View More Recent Stories

Dec 7, 2023 06:59AM Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Compared to Chemotherapy in Microsatellite Instability–High or Mismatch Repair Defi
Dec 7, 2023 06:30AM Bristol-Myers Squibb (BMY) raises repurchase plan by $3 billion
Dec 7, 2023 06:30AM Bristol Myers Squibb Announces Additional $3 Billion Share Repurchase Authorization
Dec 6, 2023 04:16PM Bristol Myers Squibb Announces Dividend Increase
Dec 5, 2023 07:00AM Bristol-Myers Squibb (BMY) Announces FDA Accepts for Priority Review Application for Opdivo in Combination with Cisplatin-Based Chemotherapy
Dec 5, 2023 06:59AM U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment
Nov 20, 2023 07:00AM Bristol-Myers Squibb (BMY) and 2seventy bio (TSVT) Provide Update on U.S. FDA Review of sBLA for Abecma
Nov 20, 2023 06:59AM Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple
Nov 16, 2023 04:57AM Bristol-Myers Squibb (BMY) Announces FDA Approval of Augtyro
Nov 15, 2023 07:20PM U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Ce
Nov 9, 2023 04:18PM Bristol Myers Squibb to Participate in the 2023 Jefferies London Healthcare Conference
Nov 9, 2023 10:15AM Bristol-Myers Squibb (BMY) Announces FDA Accepts for Priority Review Application for Breyanzi for R/R CLL or SLL
Nov 9, 2023 10:14AM U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Nov 6, 2023 06:59AM Bristol Myers Squibb to Present Data from Innovative Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2023
Nov 2, 2023 11:34AM Bristol Myers Squibb’s First Disclosures and New Data at ASH 2023 Highlight Company’s Leadership and Progress in Cell Therapy, Targeted Protein Degradation and Novel Approaches in Hematology
Nov 2, 2023 06:59AM Bristol Myers Squibb to Participate in the 2023 UBS BioPharma Conference
Nov 1, 2023 05:45AM Bristol-Myers Squibb (BMY) Appoints Christopher Boerner as Board Chair
Oct 31, 2023 06:25PM Bristol Myers Squibb Appoints Christopher Boerner, Ph.D., to Chair of the Board of Directors, Effective April 1, 2024
Oct 30, 2023 08:02AM Karyopharm Therapeutics (KPTI) Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD™ Agent CC- 92480 Mezigdomide in Combination with Selinexor
Oct 30, 2023 08:00AM Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD™ Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory M
Oct 30, 2023 07:00AM Bristol-Myers Squibb (BMY) Announces EMA Validates Application for Opdivo in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastati
Oct 30, 2023 06:59AM European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unr
Oct 26, 2023 06:59AM Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
Oct 24, 2023 06:59AM Bristol-Myers Squibb (BMY) Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA1 Antagonist for Progressive Pulmonary Fibrosis
Oct 24, 2023 06:59AM Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA1 Antagonist for Progressive Pulmonary Fibrosis
Oct 19, 2023 06:59AM Bristol-Myers Squibb (BMY) Reports Phase 3 CheckMate -67T Trial of Subcutaneous Nivolumab Meets Co-Primary Endpoints
Oct 19, 2023 06:59AM Phase 3 CheckMate -67T Trial of Subcutaneous Nivolumab (nivolumab and hyaluronidase) Meets Co-Primary Endpoints in Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Oct 18, 2023 04:15PM The Robert A. Winn Diversity in Clinical Trials Award Announces Third Group of Physicians in Program to Increase Diversity in Clinical Trials
Oct 17, 2023 03:51PM Neoadjuvant Opdivo (nivolumab) with Chemotherapy Provides Benefits for Patients with Resectable Non-Small Cell Lung Cancer Across PD-L1 Expression Levels with Three-Year Follow Up in CheckMate -816 Tr
Oct 17, 2023 03:50PM Bristol-Myers Squibb (BMY) Announces Opdivo in Combination with Cisplatin-Based Chemotherapy Followed by Opdivo Demonstrates Significant Survival Benefits for Cisplatin-Eligible Patients with Unresect
Oct 17, 2023 03:48PM Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Followed by Opdivo Demonstrates Significant Survival Benefits for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothe
Oct 17, 2023 03:26PM Bristol-Myers Squibb (BMY) Announces Perioperative Regimen of Neoadjuvant Opdivo and Chemo Followed by Adjuvant Opdivo Shows Significant Improvement in EFS for Patients with Resectable NSCLC
Oct 17, 2023 03:23PM Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Shows Significant Improvement in Event-Free Survival for Patients with Resectable Non-Small Cell Lu
Oct 13, 2023 09:18PM U.S. Food and Drug Administration Approves Opdivo® (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma¹
Oct 12, 2023 07:15AM Bristol Myers Squibb to Showcase Data Demonstrating Improved Outcomes in Earlier Stages of Cancer, Durable Long-Term Benefits with Opdivo-Based Regimens, and Addressing High Unmet Needs in Multiple Tu
Oct 12, 2023 05:37AM Bristol-Myers Squibb (BMY) Reports Sotyktu Long-Term Data Demonstrate Durable Efficacy and Consistent Safety for up to Three Years in Moderate-to-Severe Plaque Psoriasis
Oct 11, 2023 06:01PM Sotyktu (deucravacitinib) Long-Term Data Demonstrate Durable Efficacy and Consistent Safety for up to Three Years in Moderate-to-Severe Plaque Psoriasis
Oct 11, 2023 05:46AM Bristol-Myers Squibb (BMY) Presents New Zeposia Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis
Oct 11, 2023 02:01AM Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis
Oct 8, 2023 08:31PM Bristol Myers Squibb (BMY) to acquire Mirati Therapeutics (MRTX) for $58/share plus CVR
Oct 8, 2023 05:16PM Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics
Sep 26, 2023 06:59AM Bristol Myers Squibb to Report Results for Third Quarter 2023 on October 26, 2023
Sep 22, 2023 06:59AM Bristol-Myers Squibb (BMY) Announces Perioperative Regimen of Neoadjuvant Opdivo and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non
Sep 22, 2023 06:59AM Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectab
Sep 20, 2023 06:59AM Bristol Myers Squibb Announces Dividend
Sep 14, 2023 08:34AM Bristol-Myers Squibb (BMY) Highlights Advancing Pipeline and Differentiated Research Platforms to Support Long-Term Sustainable Growth at R&D Day
Sep 14, 2023 08:30AM Bristol Myers Squibb Highlights Advancing Pipeline and Differentiated Research Platforms to Support Long-Term Sustainable Growth at R&D Day
Sep 11, 2023 06:59AM Bristol-Myers Squibb (BMY) Reports Six-Year Outcomes from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo Plus Yervoy
Sep 11, 2023 06:59AM Six-Year Outcomes from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in the First-Line Treatment of Patients with Metastatic Non-Small
Sep 10, 2023 05:17AM Bristol-Myers Squibb's (BMY) LPA1 Antagonist Reduces Rate of Lung Function Decline in Progressive Pulmonary Fibrosis Cohort of Phase 2 Study
View More Recent Stories View Older Stories